International Stem Cell (ISCO) Capital Expenditures Growth (3y) (2013 - 2024)
International Stem Cell (ISCO) Capital Expenditures Growth (3y) (2013 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -45.93% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -40.95% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 29.63% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 19.18% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.08% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 60.74% |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 154.58% |
| Sep 30, 2023 | 91.29% |
| Jun 30, 2023 | 38.98% |
| Mar 31, 2023 | 71.00% |
| Dec 31, 2021 | -29.05% |
| Dec 31, 2020 | -44.18% |
| Sep 30, 2020 | -58.99% |
| Jun 30, 2020 | -28.51% |
| Mar 31, 2020 | -27.89% |
| Dec 31, 2019 | -21.35% |
| Sep 30, 2019 | 2.11% |
| Jun 30, 2019 | -18.61% |
| Mar 31, 2019 | -1.67% |
| Dec 31, 2018 | 110.55% |
| Sep 30, 2018 | 10.06% |
| Jun 30, 2018 | 102.99% |
| Mar 31, 2018 | 56.05% |
| Dec 31, 2017 | -6.35% |
| Sep 30, 2017 | -12.97% |
| Jun 30, 2017 | -36.70% |